Paul Friedman, Md

Biography

Dr. Friedman has been Chairman and Chief Executive Officer of Madrigal Pharmaceuticals since July 2016. Dr. Friedman served as Chief Executive Officer of Incyte from 2001 and was President of the company from 2004 until his retirement in January 2014. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman is also a director of public companies Incyte Corporation, Cerulean Pharma, Synta Pharmaceuticals and Verastem, and private biopharmaceutical company Gliknik. Dr. Friedman was a director of Bausch & Lomb, Sirtris Pharmaceuticals, Durata Therapeutics and Auxilium Pharmaceuticals until the acquisition of each of these companies. Dr. Friedman received his AB in Biology from Princeton University and his MD from Harvard Medical School. Dr. Friedman has been Chairman and Chief Executive Officer of Madrigal Pharmaceuticals since July 2016. Dr. Friedman served as Chief Executive Officer of Incyte from 2001 and was President of the company from 2004 until his retirement in January 2014. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman is also a director of public companies Incyte Corporation, Cerulean Pharma, Synta Pharmaceuticals and Verastem, and private biopharmaceutical company Gliknik. Dr. Friedman was a director of Bausch & Lomb, Sirtris Pharmaceuticals, Durata Therapeutics and Auxilium Pharmaceuticals until the acquisition of each of these companies. Dr. Friedman received his AB in Biology from Princeton University and his MD from Harvard Medical School.

Research Interest

Business